Apexcel Solutions
  • Home
  • About
  • Services
    • Loan Advisory
    • Fundraising
    • Management Consulting
    • Specialist Services
  • News Room
  • Contact
August 20, 2020

See-Mode raises US$7M Series A to help clinicians better predict risk of stroke, vascular diseases

Singapore- and Australia-based medtech startup, See-Mode Technologies, announced today it has raised a US$7 million Series A funding, led by Mass Mutual Ventures Southeast Asia (MMV SEA).

Other participants in the round include existing investors Blackbird Ventures, Cocoon Capital, Entrepreneur First, and SGInnovate, besides a group of angels.

This brings See-Mode’s total funding to date to US$8 million, which also included a US$1M seed round raised in 2018.

As per a press statement, the company plans to use the fresh funds for expansion into the American and European markets, R&D, hire people and build its sales and business development team.

It is also broadening its partnerships to more research institutions around the world.

Founded in 2017 by Dr Mohammadzadeh and Dr Sadaf Monajemi, See-Mode uses Artificial Intelligence (AI) to help clinicians better predict the risk of stroke and vascular diseases.

Around the world, stroke remains a leading cause of death and disability. To help clinicians better predict the risk of stroke and vascular diseases, See-Mode is developing novel solutions to improve the analysis of routinely collected medical images such as ultrasound, CT and MRI scans.

See-Mode’s software applies AI and computational models on these medical images, allowing clinicians to obtain critical stroke risk factors that may not be accessible in current clinical practice.

This allows doctors to efficiently decide on the optimal treatment for patients, improving patient care and outcomes, without the need for additional tests.

Its debut product, Augmented Vascular Analysis (AVA), is a medical AI software for automated analysis and reporting of vascular ultrasound scans.

“20 per cent of stroke patients go on to have another stroke within five years. Tackling stroke is no small feat. We are lucky to be working with an outstanding group of clinicians from leading research institutions globally to further validate our products,” Mohammadzadeh said.

AVA is awaiting regulatory approval in several markets, including Europe and the US.

Additionally, the company is building two other new products — to detect vulnerable plaque using Machine Learning and to identify high-risk blood flow using computational modelling.

Source

Taiwan’s enterprise AI firm iKala raises US$17M for expansion into Indonesia, Malaysia Ricult secures US$2M pre-Series A to help farmers increase yield, access online markets in Thailand

Related Posts

News

Highlights of Singapore Budget 2021

News

What Is A SPAC? A Simple Guide To This Investment Trend

News

A Simple Guide to Sources of Capital Raising in Singapore

Latest News

  • Highlights of Singapore Budget 2021
    February 16, 2021
  • What Is A SPAC? A Simple Guide To This Investment Trend
    January 18, 2021
  • A Simple Guide to Sources of Capital Raising in Singapore
    January 7, 2021
  • What are Unsecured and Secured Business Loans?
    December 16, 2020

Search for news:

Past News

  • February 2021
  • January 2021
  • December 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019

Search by date:

June 2022
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
27282930  
« Feb    
© Apexcel Solutions 2022
Use of this site constitutes acceptance of our Terms of Service and Privacy Policy.
We are currently updating our website to serve you better.